URS
NBIX icon

Utah Retirement Systems’s Neurocrine Biosciences NBIX Stock Holding History

Utah Retirement Systems’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.53M Sell
14,984
-736
-5% -$109K 0.02% 494
2026
Q1 		$2.07M Sell
15,720
-261
-2% -$34.6K 0.02% 552
2025
Q4 		$2.27M Hold
15,981
– – 0.02% 537
2025
Q3 		$2.24M Sell
15,981
-321
-2% -$43.5K 0.02% 541
2025
Q2 		$2.05M Sell
16,302
-281
-2% -$32.2K 0.02% 543
2025
Q1 		$1.83M Hold
16,583
– – 0.02% 569
2024
Q4 		$2.26M Buy
16,583
+100
+0.6% +$12.4K 0.02% 534
2024
Q3 		$1.9M Hold
16,483
– – 0.02% 575
2024
Q2 		$2.27M Sell
16,483
-200
-1% -$27.4K 0.03% 508
2024
Q1 		$2.3M Hold
16,683
– – 0.03% 526
2023
Q4 		$2.2M Hold
16,683
– – 0.03% 521
2023
Q3 		$1.88M Buy
16,683
+100
+0.6% +$10.5K 0.03% 538
2023
Q2 		$1.56M Sell
16,583
-200
-1% -$19.5K 0.02% 612
2023
Q1 		$1.7M Hold
16,783
– – 0.02% 583
2022
Q4 		$2M Sell
16,783
-200
-1% -$23.4K 0.03% 488
2022
Q3 		$1.8M Buy
16,983
+300
+2% +$30.4K 0.03% 512
2022
Q2 		$1.63M Hold
16,683
– – 0.03% 553
2022
Q1 		$1.56M Sell
16,683
-300
-2% -$25.4K 0.02% 617
2021
Q4 		$1.45M Hold
16,983
– – 0.02% 677
2021
Q3 		$1.63M Sell
16,983
-800
-4% -$75.6K 0.02% 630
2021
Q2 		$1.73M Buy
17,783
+100
+0.6% +$9.59K 0.02% 636
2021
Q1 		$1.72M Sell
17,683
-800
-4% -$83.9K 0.02% 614
2020
Q4 		$1.77M Buy
18,483
+800
+5% +$77.3K 0.03% 567
2020
Q3 		$1.7M Buy
17,683
+200
+1% +$23.1K 0.03% 526
2020
Q2 		$2.13M Buy
17,483
+300
+2% +$33.2K 0.04% 415
2020
Q1 		$1.49M Hold
17,183
– – 0.03% 463
2019
Q4 		$1.85M Hold
17,183
– – 0.03% 521
2019
Q3 		$1.55M Buy
17,183
+100
+0.6% +$9.34K 0.03% 558
2019
Q2 		$1.44M Buy
17,083
+102
+0.6% +$8.38K 0.03% 594
2019
Q1 		$1.5M Buy
16,981
+381
+2% +$31.8K 0.03% 558
2018
Q4 		$1.19M Buy
16,600
+100
+0.6% +$9.58K 0.03% 583
2018
Q3 		$2.03M Hold
16,500
– – 0.04% 456
2018
Q2 		$1.62M Hold
16,500
– – 0.03% 527
2018
Q1 		$1.37M Buy
16,500
+200
+1% +$16.9K 0.03% 576
2017
Q4 		$1.26M Buy
16,300
+300
+2% +$20.5K 0.03% 621
2017
Q3 		$980K Hold
16,000
– – 0.02% 683
2017
Q2 		$736K Buy
16,000
+300
+2% +$14.6K 0.02% 799
2017
Q1 		$680K Hold
15,700
– – 0.02% 794
2016
Q4 		$608K Buy
15,700
+100
+0.6% +$4.53K 0.02% 819
2016
Q3 		$790K Hold
15,600
– – 0.02% 720
2016
Q2 		$709K Buy
+15,600
New +$718K 0.02% 750

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Utah Retirement Systems's NBIX Position: Q2 2026 in Review

Utah Retirement Systems reduced its Neurocrine Biosciences (NBIX) stake by 4.7% in Q2 2026, selling an estimated $109K and leaving 14,984 shares worth $2.53M. The position accounts for 0.02% of the portfolio, ranked #494.

Utah Retirement Systems first reported a position in NBIX in Q2 2016 and has held it in 41 quarters since. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Utah Retirement Systems held 14,984 shares of Neurocrine Biosciences worth $2.53M as of Q2 2026.
  • Utah Retirement Systems sold 736 Neurocrine Biosciences shares in Q2 2026, an estimated $109K.
  • Neurocrine Biosciences made up 0.02% of Utah Retirement Systems's portfolio in Q2 2026, its #494 holding.
  • Utah Retirement Systems first reported a position in Neurocrine Biosciences in Q2 2016 and has held it in 41 quarters since.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Utah Retirement Systems's 13F filing for Q2 2026, filed 14 Aug 2026.